Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA
J Natl Compr Canc Netw. 2018 16 (10): 1216-1247

PMID: 30323092 · PMCID: PMC6438378 · DOI:10.6004/jnccn.2018.0078

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period. This portion of the guidelines describes recommendations regarding the management of anthracycline-induced cardiotoxicity and lymphedema. In addition, recommendations regarding immunizations and the prevention of infections in cancer survivors are included.

Copyright © 2018 by the National Comprehensive Cancer Network.

MeSH Terms (18)

Anthracyclines Antibiotics, Antineoplastic Antineoplastic Agents, Immunological Bacterial Infections Cancer Survivors Cardiotoxicity Humans Immunocompromised Host Lymphedema Mass Screening Medical Oncology Neoplasms Risk Assessment Societies, Medical Survivorship United States Vaccination Virus Diseases

Connections (1)

This publication is referenced by other Labnodes entities: